Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Free Report)’s share price fell 3% on Tuesday . The company traded as low as $2.22 and last traded at $2.28. 11,568 shares traded hands during mid-day trading, a decline of 6% from the average session volume of 12,338 shares. The stock had previously closed at $2.35.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Thursday, August 15th.
Get Our Latest Research Report on ARMP
Armata Pharmaceuticals Trading Up 0.9 %
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.13). Research analysts predict that Armata Pharmaceuticals, Inc. will post -1.02 EPS for the current year.
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Further Reading
- Five stocks we like better than Armata Pharmaceuticals
- Election Stocks: How Elections Affect the Stock Market
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- There Are Different Types of Stock To Invest In
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Quiet Period Expirations Explained
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.